Weekly Update Week Commencing 15/10/2012 Important Information Event Type Event Details
Following the merger of Melrose Resources plc with
Petroceltic International plc ISAs have been credited with
This stock is listed on the Alternative Investment Market and also the Enterprise Securities Market of the Dublin Stock Exchange, neither of which is an HMRC recognised stock exchange. The stock is not eligible to be held in an ISA.
Client reply deadline: 1 November 2012.
Options are: 1. To sell the holding and re-invest the proceeds in a qualifying stock of your choice (our standard commission fee will apply). 2. To sell the holding and retain the proceeds in your ISA for future investment (our standard commission fee will apply). 3. To re-register the holding into your own name. We will send you a share certificate in due course (our standard re- registration fee of £15.00 will apply). 4. To transfer the holding to your MarketMaster Account if you currently have one (no fee will be charged).
Covered Warrants Market Rumours Scrip Dividends Event Type Event Details
Terms: 1 new share for every 68.942 shares held
Scrip reference price is 241.3 Pence per share
Terms: 1 new share for every 36.897 shares held
Scrip reference price is 341.3 pence per shares
Terms: 0.0344603 new share For 1 share held
Terms: 0.015825 new share for 1 share held
Company Announcements Event Type Event Details Effective Date: 26 October 2012
Henderson confirm that the fund will merge with the Henderson Asian Growth Fund A2 USD
Shareholders will receive new shares in Henderson Asian Growth Fund A2 USD at a rate to be determined.
We will update you upon receipt of further information.
Shareholders have received a payment of £111.80 per share redeemed.
Your account has been updated accordingly.
Expected Key Dates: General Meeting : 24 October 2012 @ 9.45 am Calculation Date : 31 August 2012 Conversion Date : 30 October 2012
The Company has announced that the D shares are expected to be converted into new ordinary shares at a rate to be determined
We will update you upon receipt of further information.
Holders have received 0.9301729660 shares for every share held.
Your account has been updated accordingly. Expected Key Dates: Company Meeting Date: 31 October 2012 @ 10am Accounts credited with new shares: 01 November 2012
Subject to shareholder approval, it is proposed that every 1000 Existing Ordinary Share of 0.0001 GBP be consolidated into 1 New Share of GBP0.10 each.
Following the consolidation, the each New Share of GBP 0.10 will be subdivided into 1 New Ordinary Share of GBP 0.0001 pence and 1 Deferred Share of GBP0.0999.
The new ordinary shares will have the same rights as the existing ordinary shares.
The deferred shares will be effectively valueless and will not be credited to your account.
Shareholders have received a payment of £ 124.60 per share held.
Your account has been updated accordingly.
Expected Timetable: First General Meeting: 23 October 2012 @ 2:30pm Calculation date: 30 October 2012 after 5pm Suspension of listing of Eclipse VCT 2 shares: 31 October 2012 @ 7.30am Second General Meeting: 31 October 2012 @ 1pm Effective date for transfer of assets & liabilities of the Eclipse VCT 2 to New Eclipse shares: 31October 2012 Admission of dealings in New Eclipse shares: 01 November 2012 Accounts credited with new shares: 01 November 2012 Cancellation of listing of shares in Eclipse VCT 2: 29 November 2012 @ 8am
Subject to shareholder approval, the Boards of Octopus Eclipse, Eclipse VCT 2, Eclipse VCT 3 and Eclipse VCT 4 intends to restructure the share capital of Octopus VCT by way of a merger with Octopus Eclipse VCT.
Eclipse VCT 2 will be placed into members' voluntary liquidation and all assets and liabilities of Eclipse VCT2 will be transferred to Eclipse in consideration for the issue of New Eclipse shares. The New Octopus Eclipse VCT shares are being issued on a relative Net Asset Value basis at a rate yet to be determined. Following the transfer, the listing of the Eclipse VCT 2 shares will be cancelled.
Following the merger becoming effective Octopus Eclipse VCT intends to offer holders the opportunity to participate in an Enhanced Share Buy Back Facility. We will update you upon receipt of further information. Expected Timetable: First General Meeting: 23 October 2012 @ 3pm Calculation date: 30 October 2012 after 5pm Suspension of listing of Eclipse VCT 3 shares: 31 October 2012 @ 7.30am Second General Meeting: 31 October 2012 @ 1.30 pm Effective date for transfer of assets & liabilities of the Eclipse VCT 3 to New Eclipse shares: 31October 2012 Admission of dealings in New Eclipse shares: 01 November 2012 Accounts credited with new shares: 01 November 2012 Cancellation of listing of shares in Eclipse VCT 3: 29 November 2012 @ 8am
Subject to shareholder approval, the Boards of Octopus Eclipse, Eclipse VCT 2, Eclipse VCT 3 and Eclipse VCT 4 intends to restructure the share capital of Octopus VCT by way of a merger with Octopus Eclipse VCT.
Eclipse VCT 3 will be placed into members' voluntary liquidation and all assets and liabilities of Eclipse VCT will be transferred to Eclipse in consideration for the issue of New Eclipse shares. The New Octopus Eclipse VCT shares are being issued on a relative Net Asset Value basis at a rate yet to be determined. Following the transfer, the listing of the Eclipse VCT 3 shares will be cancelled.
Following the merger becoming effective Octopus Eclipse VCT intends to offer holders the opportunity to participate in an Enhanced Share Buy Back Facility. We will update you upon receipt of further information.
Expected Timetable: First General Meeting: 23 October 2012 Calculation date: 30 October 2012 after 5pm Suspension of listing of Eclipse VCT 4 shares: 31 October 2012 @ 7.30am Second General Meeting: 31 October 2012 Effective date for transfer of assets & liabilities of the Eclipse VCT 4 to New Eclipse shares: 31October 2012 Admission of dealings in New Eclipse shares: 01 November 2012 Accounts credited with new shares: 01 November 2012 Cancellation of listing of shares in Eclipse VCT 4: 29 November 2012
Subject to shareholder approval, the Boards of Octopus Eclipse, Eclipse VCT 2, Eclipse VCT 3 and Eclipse VCT 4 intends to restructure the share capital of Octopus VCT by way of a merger with Octopus Eclipse VCT.
Eclipse VCT 4 will be placed into members' voluntary liquidation and all assets and liabilities of Eclipse VCT will be transferred to Eclipse in consideration for the issue of New Eclipse shares. The New Octopus Eclipse VCT shares are being issued on a relative Net Asset Value basis at a rate yet to be determined. Following the transfer, the listing of the Eclipse VCT 4 shares will be cancelled.
Following the merger becoming effective Octopus Eclipse VCT intends to offer holders the opportunity to participate in an Enhanced Share Buy Back Facility. We will update you upon receipt of further information. Expected Key Dates: Effective Date: 2 November 2012
Them Allianz UK Equity Fund will merge into the Allianz RiskMaster Moderate Fund.
We will update you with the rate at which you have received your new Allianz RiskMaster Moderate Fund units
Expected Key Dates: Effective Date: 2 November 2012
The Allianz UK Index Fund Acc will merge into the Allianz RiskMaster Conservative Fund.
We will update you with the rate at which you have received your new Allianz RiskMaster Conservative Fund units
Expected Key Dates: Effective Date: 2 November 2012
The Allianz UK Growth Fund Acc will merge into the Allianz RiskMaster Growth Fund.
We will update you with the rate at which you have received your new Allianz RiskMaster Growth Fund units
Expected Key Dates: Effective Date: 9 November 2012
The Aviva Investors UK Ethical Fund Cl A will merge into a newly created sub fund with same fund name.
We will update you with the rate at which you have received your new Aviva Investors UK Ethical Fund Cl A units.
Shareholders have received a payment of £125.50 per share held.
Your account has been updated accordingly.
A Liquidation Payment of £0.01060847 share has been received.
Your account has been updated accordingly. Expected Key Dates: General Meeting Date: 02 November 2012 @ 10am
Subject to shareholder approval, each existing ordinary share will be subdivided into 1 new ordinary share of 0.01 pence and 1 B deferred share of 0.99 pence each.
The new ordinary shares will have the same rights as the existing ordinary shares.
The deferred shares will effectively be valueless and will not be credited to your account.
Expected Key Dates: Ex date: 22 October 2012 Pay Date: 25 October 2012 Admission of Shellproof PLC to trading on AIM: 25 October 2012
Shareholders will receive 1 New Shellproof Plc share for each existing Shellproof Limited share held immediately prior to merger.
Expected Key dates : Court Meeting: 17 October 2012 @ 11am General Meeting: 17 October 2012 @ 11.15am Last day of dealings in, and for registration of transfers: 05 November 2012 Disablement in CREST of Maxima Shares: 06 November 2012 @ 7am Trading in Maxima Shares on AIM suspended :06 November 2012 @ 7am Scheme Court Hearing: 06 November 2012 Scheme Record Time: 08 November 2012 @ 6pm Reduction Court hearing : 09 November 2012 Effective date of Scheme: 09 November 2012 Cancellation of admission of Maxima Shares to trading on AIM: 12 November 2012 @ 7am Commencement of dealings in New Redstone Shares on AIM: 12 November 2012 @ 8am Pay date: 12 November 2012 (expected) Long Stop Date: 14 December 2012
This is a recommended acquisition of Maxima Holding PLC by Redstone PLC.
Subject to shareholder and court approval, holders will receive 28 New Redstone Shares for each share held.
If you are not a resident in the UK, you may be subject to laws of your own country that require you to seek permission before accepting the outcome of this Scheme of Arrangement.
A Liquidation Payment of 0.066 pence per share has been received.
Your account has been updated accordingly.
A Liquidation Payment of 1.88 pence per share has been received.
Your account has been updated accordingly.
A Liquidation Payment of GBP0.0003454 per share has been received.
Your account has been updated accordingly.
UPDATE TO CORPORATE ACTION REFERENCE: 201202280
Shareholders have received a payment of £1 per share held.
Your account has been updated accordingly.
Shareholders have received 1 new ITWP Acquisitions ordinary shares for every 1 existing share held.
Your account has been updated accordingly.
Shareholders have received 1 new ITWP Acquisitions ordinary shares for every 1 existing share held.
Your account has been updated accordingly. Expected Key Dates: Court Meeting: 17 October 2012 @ 11.30am General Meeting:17 October 2012 @ 12 noon First Court Hearing to sanction the Scheme and confirm the reduction in the share capital of Man: 05 November 2012 Last day of dealings in Man Ordinary Shares : 05 November 2012 Admission of New Man Ordinary Shares to listing on the premium listing segment: 06 November 2012 @ 8am Admission to trading of the New Man Ordinary Shares on the main market of the London Stock Exchange: 06 November 2012 Pay date: 06 November 2012 Second Court Hearing to confirm the New Man Reduction of Capital: 07 November 2012 New Man Reduction of Capital becomes effective : 8 November 2012
Subject to shareholder and Court approvals, shareholders will exchange their existing ordinary shares in Man Group PLC for shares in New Man on one for one basis.
If you are not a resident in the UK, you may be subject to laws of your own country that require you to seek permission before accepting the outcome of this Scheme of Arrangement. Company Updates Event Type Event Details
UPDATE TO CORPORATE ACTION REFERENCE: 201005158
A Liquidation Payment of £0.00946875 per share has been received.
Your account has been updated accordingly.
UPDATE TO CORPORATE ACTION REFERENCE: 201201414
Shareholders have received 1.252405 new shares for every 1 share
Your account has been updated accordingly.
UPDATE TO CORPORATE ACTION REFERENCE: 201103556
Shareholders have received £3.12942943 per share
Your account has been updated accordingly.
SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING1.2. Relevant identified uses of the substance or mixture and uses advised againstPreservation of exterior timber surfaces. Applied by brush. See container for details. Not recommended for interior use on large surface areas or in confined spaces without suitable respiratory protection. 1.3. Details of the s
teroids, ACTH, licorice in large amounts, or prolonged use of laxatives. Digitalis therapy may (furosemide) Tablets 20, 40, and 80 mg exaggerate metabolic effects of hypokalemia, especially myocardial effects. All patients receiving LASIX therapy should be observed for these signs or symptoms of fluid or LASIX® (furosemide) is a potent diuretic which, if given in excessive amounts, can lea